Landmark Study Finds Common Stroke Cause is Deep Brain Vessel Damage, Not Arterial Plaque

For decades, a fundamental assumption has guided the prevention of ischemic strokes: fatty plaques build up, arteries narrow, and blood flow to the brain is choked off. This model has saved countless lives, dictating the widespread prescription of aspirin and other blood thinners. But for a specific, highly common type of stroke that occurs deep within the brain, this standard preventive playbook has consistently fallen short, leaving doctors frustrated and patients vulnerable to recurrent brain injury and cognitive decline.[1]

Now, a landmark study published in the journal Circulation has upended the traditional understanding of these events, known as lacunar strokes. Researchers from the University of Edinburgh and the UK Dementia Research Institute have discovered that lacunar strokes are not driven by the clogging of arteries with fatty cholesterol plaques. Instead, the culprit is a completely different structural failure: the microscopic blood vessels deep inside the brain become abnormally enlarged, widened, and damaged.[1]

The discovery marks a major paradigm shift in neurology. Lacunar strokes account for roughly one-quarter of all ischemic strokes—translating to about 35,000 cases annually in the United Kingdom alone. Because they occur in the brain's deep white matter, they are a primary driver of long-term disability, vascular dementia, and mobility loss. By identifying the true mechanical failure behind these strokes, scientists have finally explained why conventional anti-clotting medications often fail to protect this specific patient population.[1][3]

To uncover this hidden mechanism, the research team deployed high-resolution magnetic resonance imaging (MRI) to track 229 patients who had recently experienced either a lacunar stroke or a mild non-lacunar stroke. The investigators scanned the participants immediately after their initial stroke and then conducted follow-up imaging a year later. This longitudinal approach allowed the team to map the exact morphology of the brain's vasculature and monitor how the tissue changed over time.[2]

The imaging data revealed a stark contrast to the prevailing medical dogma. The researchers found absolutely no association between the narrowing of large arteries—the classic hallmark of atherosclerosis—and the occurrence of lacunar strokes. While fatty narrowing was indeed present in patients who suffered other types of strokes, it did not predict the deep-brain infarcts that characterize lacunar disease.[2]

Instead, the scans pointed to a phenomenon known as ectasia, or arterial widening. Patients whose deep brain penetrating arteries exhibited this abnormal enlargement were more than four times as likely to have suffered a lacunar stroke compared to those with normal or narrowed vessels. The widened arteries were structurally compromised, struggling to maintain the precise regulation of blood flow required by the brain's delicate deep-tissue networks.[2][3]

The consequences of this structural degradation were alarming. The study found that arterial widening was tightly correlated with a faster progression of cerebral small vessel disease (SVD). Even more concerning, over 25 percent of the participants developed new, asymptomatic "silent" strokes during the one-year follow-up period. These microscopic areas of tissue death accumulated quietly, steadily eroding the brain's cognitive reserves even while the patients were actively taking standard stroke-prevention medications.[3]

This high rate of breakthrough strokes perfectly illustrates the limitations of the old paradigm. Standard antiplatelet drugs like aspirin are designed to prevent platelets from clumping together and forming clots around ruptured fatty plaques. But if the underlying pathology is the structural widening and weakening of the vessel wall itself—rather than a plaque-induced clot—blood thinners offer little to no protection. In some cases of severe microvascular fragility, they might even increase the risk of microscopic bleeding.[1]

"This study provides strong evidence that lacunar stroke is not caused by fatty blockage of larger arteries, but by disease of the small vessels within the brain itself," explained Professor Joanna Wardlaw, a leading neuroimaging expert at the University of Edinburgh. Recognizing this distinction, she noted, highlights the urgent need to abandon one-size-fits-all stroke protocols and develop targeted therapies that specifically repair and support the brain's microvasculature.[1]

The implications extend far beyond acute stroke care, touching on one of the most pressing crises in global health: the rise of dementia. Cerebral small vessel disease is a leading cause of vascular cognitive impairment. As the deep penetrating arteries widen and lose their elasticity, they fail to adequately clear metabolic waste from the brain's white matter. Over time, this chronic poor perfusion and waste buildup severs the critical communication pathways between different brain regions.[4]

Armed with this new mechanical understanding, the medical community is already pivoting toward novel treatment strategies. The most prominent effort is the LACunar Intervention Trial 3 (LACI-3), a massive Phase III clinical trial currently enrolling patients across 60 hospitals in the UK. Funded by the National Institute for Health and Care Research, LACI-3 is the first trial of its kind to directly target the endothelial health of the brain's smallest blood vessels.[4]

Rather than developing entirely new compounds from scratch, the LACI-3 investigators are testing two existing, widely available medications: cilostazol and isosorbide mononitrate. Cilostazol is currently used to treat poor circulation in the legs, while isosorbide mononitrate is a standard daily treatment for angina, or chest pain caused by restricted cardiac blood flow. Both drugs have demonstrated a unique ability to improve the function of the endothelial cells that line the inner walls of blood vessels.[3][4]

Early phase trials showed highly promising results, suggesting that taking these two drugs in combination could stabilize the brain's microvasculature, reduce the rate of recurrent strokes, and preserve cognitive function. The current Phase III trial aims to recruit 1,300 participants and track them over 18 months, with cognitive preservation serving as the primary endpoint. If successful, the trial could immediately revolutionize the standard of care, as both drugs are already proven safe and are inexpensive to produce.[4]

Patient advocacy groups have hailed the Edinburgh findings as a critical turning point. Maeva May, director of policy for the Stroke Association, emphasized that while stroke remains a leading cause of complex adult disability, it is chronically underfunded compared to other neurological conditions. Breakthroughs that clarify the exact biological triggers of stroke are essential for attracting the investment needed to move therapies from the laboratory to the clinic.[1]

For the millions of aging adults at risk of small vessel disease, the demystification of lacunar strokes offers a profoundly hopeful outlook. By discarding the flawed assumption that all strokes are plumbing problems caused by clogged pipes, researchers have opened a new frontier in vascular neurology. The focus has shifted from merely thinning the blood to actively healing the blood vessels, promising a future where the brain's deepest networks can be protected against the ravages of time and disease.[4]